Jane Hollingsworth

Ms. Hollingsworth has been a director of the Science Center since 2010, and has served as a Vice Chair since 2018. She is Managing Partner of Militia Hill Ventures, a business focused on building and growing high quality life sciences companies, and is the former Executive Chair of Talee Bio, a gene therapy company with a focus on cystic fibrosis and diseases of the lung that was acquired by Roivant Sciences in 2019 and renamed Spirovant Sciences.

She is also the former Executive Chair of Immunome Inc., a cancer immunotherapy company, and co-founder and former CEO of NuPathe Inc., a publicly traded biopharmaceutical company focused on diseases of the central nervous system and sold to Teva in 2014. Ms. Hollingsworth also co-founded and served as Executive Vice President of Auxilium Pharmaceuticals, a biopharmaceutical company focused on urology and sold to Endo in 2015.

Prior to launching and leading multiple successful biopharmaceutical companies, Ms. Hollingsworth was Vice President, Secretary and General Counsel of IBAH, Inc., a publicly-traded, multinational clinical research organization. Before joining IBAH, she practiced law at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.

Ms. Hollingsworth is one of the leaders of the Greater Philadelphia entrepreneurial and life sciences communities and serves on various industry and community boards, including DS Biopharma, the Kimmel Center for the Performing Arts, and Breastcancer.Org.

She holds a B.A. from Gettysburg College and a J.D. from the Villanova University School of Law.